FGFR1 and PROKR2 rare variants found in patients with combined pituitary hormone deficiencies
View/ Open
Author
Correa, Fernanda A
Trarbach, Ericka B
Tusset, Cintia
Latronico, Ana Claudia
Montenegro, Luciana R
Carvalho, Luciani R
Franca, Marcela M
Otto, Aline P
Costalonga, Everlayny F
Brito, Vinicius N
Abreu, Ana Paula
Nishi, Mirian Y
Jorge, Alexander A L
Arnhold, Ivo J P
Sidis, Yisrael
Pitteloud, Nelly
Mendonca, Berenice B
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1530/EC-15-0015Metadata
Show full item recordCitation
Correa, F. A., E. B. Trarbach, C. Tusset, A. C. Latronico, L. R. Montenegro, L. R. Carvalho, M. M. Franca, et al. 2015. “FGFR1 and PROKR2 rare variants found in patients with combined pituitary hormone deficiencies.” Endocrine Connections 4 (2): 100-107. doi:10.1530/EC-15-0015. http://dx.doi.org/10.1530/EC-15-0015.Abstract
The genetic aetiology of congenital hypopituitarism (CH) is not entirely elucidated. FGFR1 and PROKR2 loss-of-function mutations are classically involved in hypogonadotrophic hypogonadism (HH), however, due to the clinical and genetic overlap of HH and CH; these genes may also be involved in the pathogenesis of CH. Using a candidate gene approach, we screened 156 Brazilian patients with combined pituitary hormone deficiencies (CPHD) for loss-of-function mutations in FGFR1 and PROKR2. We identified three FGFR1 variants (p.Arg448Trp, p.Ser107Leu and p.Pro772Ser) in four unrelated patients (two males) and two PROKR2 variants (p.Arg85Cys and p.Arg248Glu) in two unrelated female patients. Five of the six patients harbouring the variants had a first-degree relative that was an unaffected carrier of it. Results of functional studies indicated that the new FGFR1 variant p.Arg448Trp is a loss-of-function variant, while p.Ser107Leu and p.Pro772Ser present signalling activity similar to the wild-type form. Regarding PROKR2 variants, results from previous functional studies indicated that p.Arg85Cys moderately compromises receptor signalling through both MAPK and Ca2 + pathways while p.Arg248Glu decreases calcium mobilization but has normal MAPK activity. The presence of loss-of-function variants of FGFR1 and PROKR2 in our patients with CPHD is indicative of an adjuvant and/or modifier effect of these rare variants on the phenotype. The presence of the same variants in unaffected relatives implies that they cannot solely cause the phenotype. Other associated genetic and/or environmental modifiers may play a role in the aetiology of this condition.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4401104/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:16120966
Collections
- HMS Scholarly Articles [17922]
Contact administrator regarding this item (to report mistakes or request changes)